Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces Third Quarter Sales 2021

10/21/2021 | 07:17am EST

F. Hoffmann-La Roche Ltd. (hereafter 'Roche') [Head Office: Basel, Switzerland. CEO: Severin Schwan] announced its third quarter sales 2021 (January 1 - September 30, 2021).

Roche owns 59.89% of Chugai's outstanding shares (61.16% of the total number of shares issued excluding treasury stock) as of the end of September 2021.

Its investor updates and presentation materials can be found on its website (https://www.roche.com).

Chugai's performance for the period of January 1 to September 30, 2021 is included in the announced Roche Group's results.

Contact:

Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group

Corporate Communications Dept.

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

Investors

Chugai Pharmaceutical Co., Ltd.

Investor Relations Group

Corporate Communications Dept.

Takayuki Sakurai

Tel: +81-3-3273-0554

E-mail: ir@chugai-pharm.co.jp

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD. 0.85% 3665 End-of-day quote.-33.40%
ROCHE HOLDING AG 0.76% 366.2 Delayed Quote.17.62%
All news about ROCHE HOLDING AG
05:12aREMINDER : Invitation to Roche's virtual analyst event during ESMO IO
PU
02:02aRoche develops new research test kits for Omicron variant
RE
01:22aRoche Unveils Three Testing Kits to Identify Omicron Variant Mutations
MT
01:13aRoche develops new test kits for COVID-19 Omicron variant
RE
01:00aRoche has rapidly developed additional testing options to differentiate mutations in th..
AQ
12/02Chugai Launches a New Educational Website 'So-Zo LABO' Aiming for a Society that Embrac..
AQ
12/02ROCHE HOLDINGS AG : UBS sticks Neutral
MD
12/01Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluati..
AQ
12/01AlphaValue/Baader Europe Lowers Price Target on Roche, Maintains Add Recommendation
MT
12/01Roche Closes Biotechnology Group TIB Molbiol Acquisition
MT
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 62 134 M 67 541 M 67 541 M
Net income 2021 15 273 M 16 602 M 16 602 M
Net cash 2021 4 368 M 4 748 M 4 748 M
P/E ratio 2021 19,8x
Yield 2021 2,57%
Capitalization 314 B 342 B 341 B
EV / Sales 2021 4,98x
EV / Sales 2022 4,87x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 363,45 CHF
Average target price 388,44 CHF
Spread / Average Target 6,88%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG17.62%341 509
JOHNSON & JOHNSON-0.18%413 555
PFIZER, INC.44.09%297 706
NOVO NORDISK A/S64.51%243 534
ELI LILLY AND COMPANY47.55%224 726
ABBVIE INC.8.18%206 612